Development pathway for biodefense vaccines

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages

  Barrett, Alan D T ^a   Beasley, David W C ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Biodefense; Vaccine development

Indexed keywords

VACCINE;

ARTICLE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; ECONOMIC ASPECT; EPIDEMIC; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HUMAN; IMMUNIZATION; LICENCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 79952223316     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.094     Document Type: Article

References (32)

1. Batson A. The costs and economics of modern vaccine development. Dev Biol 2002;110:15-24.
2. Struck MM. Vaccine research and product development success rates and development times. Nat Biotechnol 1996;14:591-3.
3. Batson A. The problems and promise of vaccine markets in developing countries. Health Affairs 2005;24:690-3.
4. Daems R, Del Giudice G, Rappuoli R. Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine 2005;23(December (50)):5732-42.
5. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007;25(12):1361-6.
6. Winther MD, Dougan G. The impact of new technologies on vaccine development. Biotechnol Genet Eng Rev 1984;2:1-39.
7. Zahradnik JM, Couch RB, Gerin JL. Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology. J Infect Dis 1987;155:903-8.
8. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116(May (5)):1167-73.
9. http://www.fda.gov/Cber/gdlns/vaccsubstrates.pdf.
10. http://www.scribd.com/doc/2761067/Notice-Reports-and-guidancedocuments-availability-etc-Plasmid-deoxyribonucleic-acid-DNA-vaccinesconsiderations-for-infectious-disease-indica.
11. http://www.fda.gov/ora/complianceref/bimo/glp/default.htm.
12. Verdier F. Non-clinical vaccine safety assessment. Toxicology 2002;174:37-43.
13. Verdier F, Barrow PC, Burge J. Reproductive toxicity testing of vaccines. Toxicology 2003;185:213-9.
14. Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 2005;23:3210-22.
15. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009;10(1):116-25.
16. http://www.fda.gov/RegulatoryInformation/Guidances/ucm125127.htm.
17. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
18. http://www.fda.gov/OHRMS/DOCKETS/98fr/053102a.htm.
19. Food and Drug Administration. HHS. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule. Fed Regist 2005;70:57505-9.
20. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078923.pdf.
21. Rosenthal SR, Clifford JC. Development of vaccines for bio-warfare agents. Dev Biol (Basel) 2002;110:99-105.
22. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. Alliance for biosecurity. The FDA animal efficacy rule and biodefense. Nat Biotechnol 2007;25:1084-7.
23. Milstien JB. Regulation of vaccines: strengthening the science base. J Public Health Policy 2004;25:173-89.
24. Milstien JB, Kaddar M, Kieny MP. The impact of globalization on vaccine development and availability. Health Affairs 2006;25:1061-9.
25. Code of Federal Regulations, in 21 CFR 312. 2005.
26. Davenport LW. Regulatory considerations in vaccine design. Pharm Biotechnol 1995;6:81-96.
27. Miller DL, Ross JJ. Vaccine INDs: review of clinical holds. Vaccine 2005;23:1099-101.
28. FDA (CBER). Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), April 1996.
29. http://www.fda.gov/Cber/regsopp/8401.htm.
30. http://www.who.int/entity/biologicals/publications/trs/areas/vaccines/en/.
31. http://www.cdc.gov/vaccinesafety/vaers/.
32. Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, Ward BJ, et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the vaccine adverse event reporting system (VAERS). Pharmacoepidemiol Drug Saf 2004;13(12):825-40.